Eloralintide
Lilly's weekly fullness shot: up to 20 percent weight loss in a year with nausea near placebo. In trials; nothing sold is the real thing.
What it is
Eloralintide gives you the big weight loss of the strongest injectables with far less of the nausea, because it copies amylin and only amylin. The one-year trial numbers are the best in the fullness class. The catch is that it is still a trial drug, and anything you can buy is a copy.
Who reaches for eloralintide: people who got real results on a GLP-1 but could not live with the nausea or the stomach slowing; people on cagrilintide who want the same effect with fewer bad weeks; and people who have plateaued on tirzepatide or retatrutide and want a second lever that does not slow the gut further. It copies amylin, the hormone your pancreas releases with insulin to tell your brain you have eaten enough. Cagrilintide does the same job but also hits the calcitonin receptor, which is where most of its nausea comes from. Eloralintide was built to skip that receptor, and in the trial that design showed.
What it feels like: food loses its pull, you stop eating sooner without deciding to, and the between-meal snacking fades. It is more a head effect than a gut effect; the stomach does not feel bricked the way it can on semaglutide. The signal starts in week one and builds for about a month at each dose because the drug accumulates. In the 48-week trial every dose beat placebo: about 9 percent weight loss at 1 mg, 12 percent at 3 mg, 18 percent at 6 mg and 20 percent at 9 mg, against 0.4 percent on placebo. Nausea at 1 and 3 mg was close to placebo. Tiredness was the other common complaint. It does nothing for muscle, so lift and eat protein, and it reverses if you stop and eat. Some people who stay on it long term report a general fatigue from extended use.
How people run it: 1 mg subQ once a week, held for four weeks, then 3 mg, which is where a lot of people stop because 12 percent with almost no nausea is a good deal. The trial stepped every four weeks up to 6 and 9 mg, and the arms that stepped slowly had less nausea for the same weight result. The half-life is about two weeks, so a step takes a month to fully land and a month to leave; that is why you never rush it. A 5 mg vial is five weeks at 1 mg, and the mixed solution is good for about a month, so buy small early and bigger later. The mistakes: starting at 3 mg because the nausea story made you cocky, stacking it on cagrilintide (same receptor, double the nausea), and raising it the same month you raised a GLP-1.
Evidence: a published phase 1 and a 48-week phase 2 in 263 adults, published in The Lancet in 2025, with weight loss from 9.5 to 20.1 percent across the dose arms and secondary improvements in waist, blood pressure, lipids and blood sugar. That is high-quality human data, but it is two trials, not a program. Phase 3 only began enrolling at the end of 2025, approval is years away, and there is no prescription route. Everything sold as eloralintide today is grey-market material copying a molecule Lilly has not finished testing.
Skip it if you have never used an injectable for weight; semaglutide and tirzepatide are approved and should come first. Skip it with a pancreatitis history, a slow stomach or a pregnancy. If you want an amylin drug that is closer to approval, cagrilintide is further along in its program and the CagriSema pairing is the one with the most data. If you are already on tirzepatide, that is the pairing Lilly itself has tested.
What people use it for
Weight loss
Some evidenceA 48-week phase 2 in 263 adults, published in The Lancet, showed 9.5 to 20.1 percent weight loss across the dose arms against 0.4 percent on placebo, with a clean dose-response. This is high-quality, placebo-controlled human data, though it is one trial of this size and phase 3 has only just begun.
Nausea and tolerability
Some evidenceThe point of the molecule. Because it is selective for the amylin receptor and largely skips the calcitonin receptor, nausea stayed mild to moderate and, at 1 and 3 mg, close to placebo. Arms that escalated slowly had less nausea for the same weight result. Fatigue was the other common complaint.
Waist, blood pressure, lipids and blood sugar
Some evidenceAll improved against placebo as secondary endpoints in the phase 2, in line with the weight loss. Nothing is known about heart outcomes, which take years and a phase 3 program to measure.
Stacked with a GLP-1
Early daysIt works on a different receptor from the GLP-1 and GIP drugs, so it should add appetite control rather than overlap, and Lilly's own pairing with tirzepatide (EloraTZP) reached up to 23.3 percent weight loss over 48 weeks in a phase 2 in type 2 diabetes, against 14.8 percent on tirzepatide alone, with more people quitting for side effects. There is no published retatrutide combination, so that stack is logic, not evidence.
How it works
Where Eloralintide sits among the amylin peptides
- A 48-week Phase 2 in 263 adults: 9.5% to 20.1% weight loss by dose, against 0.4% on placebo
- Nausea was mild to moderate, and near placebo at the 1 mg and 3 mg doses
- Waist, blood pressure, lipids, and blood sugar improved alongside the weight
- Still investigational, Phase 3 began enrolling at the end of 2025, so long-term safety is unsettled
How people use it
Safety, in brief
Things people sometimes notice
- Mild nausea, mainly in the week after a dose increase
- Eating noticeably less without trying, which is the effect
- Tiredness in the first weeks, the second most common complaint in the trial, and in some people with long use
- Constipation or loose stools while the gut adjusts
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept